3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
4
Lung Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Lymphoproliferative Disorders
1
Glioma
1
Adenocarcinoma of Lung
1
Interventions
Doxorubicin
15
pembrolizumab
12
Cyclophosphamide
9
Surgical Procedures, Operative
8
Gemcitabine
8
Blood Specimen Collection
8
Ifosfamide
7
Surveys and Questionnaires
6
Nivolumab
6
Trabectedin
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Drug Therapy
5
fludarabine
4
Temozolomide
4
Specimen Handling
4
Radiation Dose Hypofractionation
4
Biopsy
4
selinexor
3
pazopanib
3
liposomal doxorubicin
3
cabozantinib
3
atezolizumab
3
anlotinib
3
Radiation
3
Observation
3
Docetaxel
3
Dacarbazine
3
trastuzumab deruxtecan
2
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Sarcoma
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled